Drug intelligence / Profile preview

TenofoBell

Development stage: Phase 4
Modality: Small Molecules
Administration: Oral

Overview

TenofoBell is a branded formulation of tenofovir disoproxil fumarate, an oral nucleotide analogue reverse transcriptase inhibitor (nRTI) used in combination antiretroviral therapy for HIV-1 infection and for the treatment of chronic hepatitis B. As a prodrug of tenofovir, it is converted intracellularly to tenofovir diphosphate, which competitively inhibits HIV-1 reverse transcriptase and hepatitis B virus polymerase, causing DNA chain termination and suppression of viral replication. The product is positioned as a generic or regional brand of tenofovir disoproxil fumarate for use in standard HIV and HBV treatment regimens.

Brand names: TenofoBell

Targets

Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on TenofoBell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TenofoBell.

Explore the full profile